IMAC Holdings, Inc. Announces Completion of Third Cohort of Its Phase I Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease

IMAC Holdings, Inc. announced it has completed the third cohort of its Phase I clinical trial for its investigational compound utilizing umbilical cord-derived allogenic MSCs for the treatment of bradykinesia due to Parkinson’s disease.